<DOC>
	<DOCNO>NCT00119379</DOCNO>
	<brief_summary>HIV lipoatrophy condition mark fat loss ; occur many patient take antiretroviral ( ARV ) therapy include nucleoside reverse transcriptase inhibitor ( NRTIs ) . Lipoatrophy may relate mitochondrial toxicity , condition damage heart , nerve , muscle , kidney , liver , affect body 's ability produce energy . NucleomaxX food supplement consist sugar cane extract high nucleoside , build block may counteract negative effect NRTIs . Tenofovir disoproxil fumarate ( TDF ) NRTI may cause less lipoatrophy drug class , zidovudine ( ZDV ) stavudine ( d4T ) . The purpose study determine whether nucleoside supplementation NucleomaxX substitution TDF ZDV d4T ARV regimen reverse fat loss cause mitochondrial toxicity HIV infect adult . Study hypotheses : 1 ) The substitution TDF d4T ZDV patient HIV lipoatrophy result increase mitochondrial DNA content fat , skeletal muscle , peripheral blood mononuclear cell ( PBMCs ) , turn lead improvement mitochondrial function assess electron transport chain ( ETC ) oxidative phosphorylation pathway ( OXPHOS ) activity . The latter lead decrease fat apoptosis mitochondrial lipid oxidative damage biomarkers . 2 ) Supplementation uridine ( via NucleomaxX ) increase mtDNA content adipose tissue increase body fat content .</brief_summary>
	<brief_title>Effectiveness Nucleoside Supplementation Substituting Tenofovir Disoproxil Fumarate Other Drugs Anti-HIV Regimens Reversing Fat Loss HIV Infected Adults</brief_title>
	<detailed_description>NRTIs important part many ARV regimen use treat HIV infect patient ; however , relationship NRTI-induced mitochondrial dysfunction lipoatrophy still unclear require additional research . Additionally , relationship gain dual-energy x-ray absorptiometry ( DEXA ) -measured limb fat mitochondrial DNA ( mtDNA ) content , mitochondrial function , fat apoptosis , oxidative damage also examine study . Patients participate study 48 week . Participants randomly assign one two group . Group 1 patient receive NucleomaxX every day . Group 2 patient substitute TDF ZDV d4T every day current stable NRTI-containing ARV regimen . NucleomaxX provide Group 1 patient , TDF ARV provide study . There 10 study visit , occur study entry Weeks 2 , 4 , 8 , 12 , 18 , 24 , 30 , 36 , 48 . Blood collection occur visit . Additionally , urine collection , DEXA scan , fat biopsy do study entry Weeks 24 48 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Diagnosis HIV lipoatrophy Receiving stable stavudine zidovudinecontaining ARV regimen HIV1 RNA viral load le 50 copies/ml Coagulopathies bleed disorder Diabetes require medication Creatinine clearance le 50 ml/min Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>lipoatrophy</keyword>
	<keyword>mitochondrion</keyword>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
</DOC>